Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 2/20 | 0.35 |
| ▸ | F9 | P00740 | 2/20 | 0.35 |
| ▸ | F10 | P00742 | 2/20 | 0.35 |
| ▸ | F12 | P00748 | 2/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.35 |
| ▸ | F7 | P08709 | 2/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.35 |
| ▸ | MMP3 | P08254 | 2/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP7 | P09237 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | NRP1 | O14786 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15432299 | 0.86 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL4082381 | 0.84 | MMP1 (0.42) | F2F9F10F12PRSS1 | |
| SCHEMBL20141818 | 0.83 | F2 (0.33) | F2F9F10F12PRSS1 | |
| SCHEMBL2922483 | 0.82 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL20259909 | 0.81 | CHRNB2 (0.33) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL4383814 | 0.80 | SLC6A1 (0.36) | CHRNB2CHRNA4CHRNA3 | |
| SCHEMBL15542301 | 0.80 | SLC6A1 (0.36) | CHRNB2CHRNA4CHRNA3 | |
| SCHEMBL3272707 | 0.80 | SLC6A1 (0.36) | CHRNB2CHRNA4CHRNA3 | |
| SCHEMBL5073006 | 0.79 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL2916330 | 0.79 | CHRNB2 (0.39) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1959960-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2008-08-27 | — | — | EP | claimed |
| WO-2007070683-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-06-21 | — | — | WO | claimed |
| EP-3100723-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20170037018-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | BIKAM PHARMACEUTICALS INC. (US) | 2017-02-09 | — | — | US | disclosed |
| US-9562022-B2 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| EP-3100723-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | Bikam Pharmaceuticals, Inc. (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-2442644-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2016-08-10 | — | — | EP | disclosed |
| EP-2442644-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | Bikam Pharmaceuticals, Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| US-20110003784-A1 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS INC. | 2011-01-06 | — | — | US | disclosed |
| WO-2010147653-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| EP-1959960-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007070683-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037018-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | CRYAB, CRYAA, UACA | CHRNB2 343/4885CHRNA4 1369/4885CHRNA7 1050/4885 |
| US-20110003784-A1 | Opsin-binding ligands, compositions and methods of use | CRYAB, CRYAA, UACA | CHRNB2 343/4885CHRNA4 1369/4885CHRNA7 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.